Related Experiment Video
Updated: Jul 21, 2025

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases
1Department of Chemistry, Indrashil University, Kadi, Mehsana 382740, Gujarat, India.
Abstract:
Amyloids were conventionally referred to as extracellular and intracellular accumulation of Aβ42 peptide, which causes the formation of plaques and neurofibrillary tangles inside the brain leading to the pathogenesis in Alzheimer's disease. Subsequently, amyloid-like deposition was found in the etiology of prion diseases, Parkinson's disease, type II diabetes, and cancer, which was attributed to the aggregation of prion protein, α-Synuclein, islet amyloid polypeptide protein, and p53 protein, respectively. Hence, traditionally amyloids were considered aggregates formed exclusively by proteins or peptides. However, since the last decade, it has been discovered that other metabolites, like single amino acids, nucleobases, lipids, glucose derivatives, etc., have a propensity to form amyloid-like toxic assemblies. Several studies suggest direct implications of these metabolite assemblies in the patho-physiology of various inborn errors of metabolisms like phenylketonuria, tyrosinemia, cystinuria, and Gaucher's disease, to name a few. In this review, we present a comprehensive literature overview that suggests amyloid-like structure formation as a common phenomenon for disease progression and pathogenesis in multiple syndromes. The review is devoted to providing readers with a broad knowledge of the structure, mode of formation, propagation, and transmission of different extracellular amyloids and their implications in the pathogenesis of diseases. We strongly believe a review on this topic is urgently required to create awareness about the understanding of the fundamental molecular mechanism behind the origin of diseases from an amyloid perspective and possibly look for a common therapeutic strategy for the treatment of these maladies by designing generic amyloid inhibitors.
Insights
Amyloids, once thought only protein-based, can form from metabolites, contributing to diverse diseases. Understanding these toxic assemblies offers potential for common therapeutic strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Pathology
Background:
- Traditionally, amyloids involved protein/peptide aggregation (e.g., Aβ42 in Alzheimer's, prion protein in prion diseases).
- Recent discoveries reveal non-protein metabolites (amino acids, lipids, etc.) also form amyloid-like toxic assemblies.
- These metabolite assemblies are implicated in metabolic disorders like phenylketonuria and Gaucher's disease.
Purpose of the Study:
- To provide a comprehensive overview of amyloid-like structure formation across various diseases.
- To elucidate the structure, formation, propagation, and transmission of extracellular amyloids.
- To raise awareness of amyloid's role in disease pathogenesis and explore common therapeutic targets.
Main Methods:
- Comprehensive literature review of studies on amyloid formation and disease.
- Analysis of molecular mechanisms underlying amyloid aggregation from proteins and metabolites.
- Synthesis of information on amyloid implications in neurodegenerative, metabolic, and other diseases.
Main Results:
- Amyloid-like structure formation is a common pathogenic mechanism across diverse syndromes, not limited to proteins.
- Metabolite-derived amyloid assemblies play significant roles in the pathophysiology of inborn errors of metabolism.
- Extracellular amyloids share common features in structure, formation, and propagation relevant to disease.
Conclusions:
- Amyloid formation is a unifying molecular mechanism underlying a wide spectrum of diseases.
- Understanding metabolite-derived amyloids is crucial for comprehending disease pathogenesis.
- Developing generic amyloid inhibitors presents a promising avenue for novel therapeutic strategies.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Atherosclerosis I: Introduction
Proteoglycans
Coronary Artery Disease II: Pathophysiology
Lysosomal Hydrolases
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

